Patients transitioning from DM management through diet with fasting blood glucose (FBG) levels between 10 and 13.9 mmol/L should initiate glucose–insulin–potassium (GIK) therapy along with additional bolus insulin in the form of rapid-acting antihyperglycemic agent (aspart or lispro). The gene discussed is INS; the disease is diabetes mellitus.